H eart failure (HF) with preserved ejection fraction (HFpEF) is common, increasing in prevalence, and is associated with significant morbidity and mortality. Left ventricular (LV) hypertrophy, left atrial (LA) enlargement, elevated LV filling pressure, and pulmonary hypertension have each been associated with worse prognosis in HFpEF. [1] [2] [3] [4] Much interest has focused on the potential therapeutic role of aldosterone antagonist therapy in HFpEF. However, limited data exist regarding the impact of aldosterone antagonist therapy on cardiac structure and function in HFpEF and on the prognostic relevance of changes in cardiac structure and function in HFpEF.
Clinical Perspective on p 1058
In the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial, treatment with spironolactone in HFpEF did not reduce the composite end point of cardiovascular death, aborted sudden death, or HF hospitalization but was associated with a lower incidence of HF hospitalization in the study population overall. 5 Cardiac structure and function was assessed by echocardiography at baseline and at 12 to18 months after randomization to either spironolactone or placebo in a subset of patients. 6 Among this subset of patients, we determined the impact of randomization to spironolactone versus placebo on measures of cardiac structure and function in HFpEF. In addition, we explored the prognostic relevance of changes in cardiac structure and function over 12 to 18 months on subsequent outcomes.
Methods

Patient Population
TOPCAT was a multicenter, international, randomized, double-blind placebo-controlled trial of spironolactone compared with placebo to reduce cardiovascular morbidity and mortality in 3445 adults at least 50 years old with signs and symptoms of HF and a left ventricular ejection fraction ≥45% per local site reading. 7 Randomization was stratified by the presence of either one of the following inclusion criteria: at least one hospitalization in the prior 12 months for which HF was a major component or, if no qualifying hospitalization, a B-type natriuretic peptide (BNP) in the prior 60 days ≥100 pg/mL or N-terminal pro-BNP ≥360 pg/mL. All patients provided written informed consent, and the study was approved by the local Institutional Review Board at each site. Baseline demographics and clinical characteristics of the trial population have been previously described in detail. 8 The design and baseline findings of the TOPCAT echocardiographic substudy, including reproducibility metrics for conventional echocardiographic measures, have been previously described in detail. 6 At 27 sites, patients consenting to participation in the overall TOPCAT trial were separately consented to participate in the echocardiographic substudy and underwent echocardiograms by a study-specific protocol at baseline and at 12 or 18 months after randomization. Of 935 patients in the TOPCAT echocardiographic study, 305 were enrolled in the dedicated substudy, in whom followup echocardiography was done at 12 months in 213 (70%) and 18 months in 31 (10%). No follow-up echocardiogram was performed in 61 patients (20%). Of the 244 substudy participants in whom a follow-up echocardiogram was performed, image quality was adequate for quantitative analysis at baseline and follow-up in 239 (performed at 12 months in 208 participants and at 18 months in 31 participants).
Echocardiographic Methods
Quantitative measurements on all study echocardiograms were performed according to the American Society of Echocardiography recommendations by dedicated analysts at the core laboratory blinded to clinical information and randomized treatment assignment as previously described. 6, 9, 10 Intra-observer variability in our laboratory for key echocardiographic measures of cardiac structure and function have been previously reported. 6
Outcomes
Clinical outcomes included cardiovascular death, HF hospitalization, and aborted sudden death during the follow-up period. All events were reported by the primary site investigator and independently adjudicated by the Clinical End Points Center. Definitions of these end points have been previously published. 7
Statistical Analysis
Continuous variables are presented as means and standard deviations or median and interquartile range as specified. Two-sided P values of <0.05 were considered significant. Change in echocardiographic measures from baseline to follow-up was calculated as the follow-up value−baseline value. The relationship between randomization to spironolactone and change in echocardiographic measures was assessed using linear regression, adjusting for the baseline value of the echocardiographic measure of interest. The TOPCAT echocardiography substudy was initially designed to have 90% power to detect a 1 cm/s difference in the change in tissue Doppler imaging e′ with spironolactone versus placebo and aimed to enroll 500 patients assuming loss to follow-up rate of 10%, inadequate image quality of 15%, standard deviation of difference 3 cm/s, and a correlation of baseline with followup measure of 0.50. Using the actual study sample size and observed standard deviation of difference and correlation between measures, we had 89% power to detect a difference in the change in e′ of 0.8 cm/s associated with spironolactone. Similarly, we had ≥80% power to detect a 2.1 U difference in change in E/e′ ratio, an 8 g difference in change in LV mass index, and a 6 mL difference in change in LA volume.
For the assessment of the prognostic implication of changes in cardiac structure and function in HFpEF, the primary outcome of the study was the composite of first occurrence of HF hospitalization, aborted sudden death, or cardiovascular death occurring after the date of the follow-up echocardiogram. Unadjusted and multivariable-adjusted Cox proportional hazards analyses were performed to determine the association of changes in cardiac structure and function with adverse outcomes. Because of relatively small numbers of events, all adjusted Cox models were adjusted for the baseline value of the echo parameter and age as continuous covariates. All other categorical variables (sex, race, region, and randomization strata) were used as stratification factors in the Cox model along with Huber-White robust variance estimators. As a sensitivity analysis, all echo parameter variables found to be significant in these adjusted models were further assessed using permutation-based P values, in which the variable representing change from baseline was randomly permuted 1000 times and the stratified Cox model used to construct the null distribution of parameters used for comparison to the observed parameter. Given the marked regional differences in patient characteristics and treatment effects noted in TOPCAT, 11 all analyses were also performed separately by geographic region (Americas versus Russia/Georgia; Data Supplement).
Results
As compared with the 3206 patients in TOPCAT without serial echocardiograms, the 239 patients with serial echocardiographic data were older and more frequently enrolled through the BNP stratum. Although sex, race, and region of enrollment were similar between groups, patients with serial echocardiographic data had a higher prevalence of prior coronary revascularization and atrial fibrillation and had lower heart rate, blood pressure, and hematocrit at baseline ( Table I in the Data Supplement).
Impact of Spironolactone on Cardiac Structure and Function
Among the 239 patients with echocardiographic data at baseline and follow-up, the 121 patients randomized to spironolactone were well-matched to the 118 randomized to placebo, with the exception of a modestly higher prevalence of hypertension among the placebo group (Table 1 ). No significant difference was noted in the number of interval in primary events between the baseline and follow-up studies between treatment arms (11 [9%] versus 4 [3%] in the placebo and spironolactone arms, respectively, P=0.07). Randomization to spironolactone compared with placebo was not associated with significant differences in measures of LV structure, LV systolic function, LV diastolic function, LA size, or RV function and pulmonary pressure ( Table 2 ). Similar findings were noted in an on-treatment analysis, excluding 38 patients who permanently discontinued study drug before the follow-up echocardiogram ( Table II in the Data Supplement) . Similar findings were also noted in analysis stratified by randomization strata (prior HF hospitalization versus elevated natriuretic peptide level; Table III in the Data Supplement). Supplemental analyses were performed separated by region of enrollment (Tables IV-VII in the Data Supplement) . Among patients enrolled in the United States, randomization to spironolactone compared with placebo was associated with modest decrease in LV end-systolic volume and E/A ratio and increase in left ventricular ejection fraction, whereas randomization to spironolactone was not associated with significant changes in cardiac structure or function among patients enrolled in Russia or Georgia ( 
Prognostic Relevance of Changes in Cardiac Structure and Function in HFpEF
Overall, participants were followed up for a median of 710 days (IQR 361-934 days) after the follow-up echocardiogram, during which time 29 primary outcome events occurred. After adjusting for baseline value, increase in LA volume was associated with a heightened risk of the primary composite end point (Table 3 ; Figure) . Associations of marginal statistical significance were also noted between increase in E/A ratio, increase in pulmonary artery systolic pressure (PASP), and decrease in RV fractional area chance and subsequent occurrence of the primary composite end point. The associations between change in LA volume and E/A ratio and the primary outcome remained statistically significant after further adjustment for patient demographics, region of enrollment, and randomization strata. The significance of change in left atrial volume in adjusted models was further supported by the permutation test, which yielded a P value of 0.033, as were changes in E/A ratio (permutation test P<0.001). Changes in PASP and RV fractional area chance were no longer associated with subsequent outcomes after adjustment. Changes in E/e′ ratio and measures of LV structure were not associated with subsequent outcomes. Increases in LA volume and PASP and decrease in left ventricular ejection fraction were associated with heightened risk of the primary end point among patients enrolled in the United States, whereas changes in echocardiographic measures were not associated with subsequent outcomes among patients enrolled in Russia or Georgia (Table VII in 
Discussion
Among 239 HFpEF patients in the TOPCAT trial with echocardiographic data at randomization and at 12-to 18-month follow-up, spironolactone therapy was not associated with major alterations in cardiac structure or function. This was true for the study population overall and among patients enrolled in the United States and those enrolled in Russia or Georgia. In the study population overall, improvements in LA volume and E/A ratio from baseline to follow-up were associated with a lower subsequent risk of the primary composite end point of marginal statistical significance.
Previous smaller studies of the impact of aldosterone antagonist therapy on cardiac structure and function in HFpEF have yielded conflicting results (Table 4 ). [12] [13] [14] [15] [16] In a study of 44 patients with HFpEF randomized to 12 months of therapy with eplerenone versus placebo, Mak et al observed no significant effect of eplerenone on LV mass index, LA volume index, or multiple measures of LV diastolic function (E/A ratio, e′ velocity, E/e′ ratio; Table 4 ), although a modest improvement in E wave deceleration time was noted. 13 In contrast, Deswal et al observed a significant improvement in the E/e′ ratio among 44 predominantly male HFpEF patients randomized to 6 months of eplerenone compared with placebo, an association that group reproduced in a follow-up study of spironolactone therapy in 48 elderly women with HFpEF. 14, 15 Notably, no treatment effect was noted on E/A ratio, LA volume, or LV mass in either of those studies. Aldosterone Receptor Blockade in Diastolic Heart Failure (ALDO-DHF), the largest and perhaps the most definitive study to investigate the impact of spironolactone on cardiac structure and function in HFpEF, demonstrated significant improvements in e′, E/e′ ratio, LV mass index, and LV size among 422 HFpEF patients randomized to 12 months of spironolactone versus placebo. 16 The reasons why the TOPCAT findings are partially discordant with those of ALDO-DHF are uncertain. The number of patients with serial studies was smaller in TOPCAT and limited our power to detect a spironolactone treatment effect. In the overall TOPCAT trial, early study drug discontinuation occurred in over 30% of participants, which would bias analyses of treatment effect toward the null. In addition, differences in inclusion criteria possibly resulted in earlier stage disease in the ALDO-DHF trial compared with TOPCAT. TOPCAT patients included in this analysis tended to be older than ALDO-DHF patients (70 versus 67 years, respectively), prior HF hospitalization was present in 62% in TOPCAT versus 37% in ALDO-DHF, and median N-terminal pro-BNP level in ALDO-DHF was lower than that in the TOPCAT inclusion criterion for patients without a prior HF hospitalization. It is possible that impairments in cardiac structure and function in HFpEF are less modifiable by spironolactone in more advanced stages of disease. Concordant with this hypothesis, several studies in patients with comorbid conditions predisposing to HFpEF-including hypertension with exertional intolerance, 17 obesity, 18 and metabolic syndrome 19 -have demonstrated improvements in LV diastolic function measures with spironolactone. This is one of the only studies, to our knowledge, to evaluate the prognostic relevance of changes in cardiac structure and function on subsequent outcomes in HFpEF. After adjusting for the baseline value, improvements in measures of LV filling pressure (LA volume, E/A ratio), pulmonary pressure (TR velocity), and RV function (RV fractional area chance) were associated with a lower risk of subsequent clinical events, with most of these associations of borderline statistical significance. These associations are not surprising because multiple studies have established the prognostic importance of elevated LV filling pressure, 4 pulmonary hypertension, 2 and RV dysfunction 20 in HFpEF. However, the demonstration that improvements in these measures relate to lower subsequent risk is novel and suggests that these may be relevant surrogates in Phase 2 HFpEF trials.
Each 1 mL reduction in LA volume was associated with a 3% lower risk of the primary end point after adjusting for baseline LA volume and remained significantly associated with similar effect estimate after additional adjustment for patient demographics and randomization strata. Our findings are consistent with prior studies demonstrating the prognostic importance of changes in LA volume in patients with HF or LV systolic dysfunction after myocardial infarction. 21 Importantly, although we did not observe an effect of spironolactone therapy on LA size, both pharmacologic 22 and exercise training 23 interventions have been shown to reduce LA size in HFpEF. Ongoing studies will determine whether these intervention-associated benefits in cardiac structure translate into improvements in clinical outcomes. Several studies have demonstrated the prognostic importance of elevated pulmonary artery pressure, 2,4 and more recently associated RV dysfunction, 20 in HFpEF. Indeed, there is considerable interest in therapies targeting the pulmonary vasculature in HFpEF patients with pulmonary hypertension, 24 although existing data are conflicting. 25, 26 However, to date, there is little data regarding the prognostic implications of reduction in PASP in HF generally, and HFpEF in particular. Therefore, although of marginal statistical significance, our finding of an association between change in PASP-independent of baseline PASP-and subsequent risk in HFpEF is intriguing. We were unable to differentiate changes in PASP related to changes in LA pressure versus changes in pulmonary vascular resistance. Replication of this finding in a larger HFpEF sample, and demonstration that the relationship between change in PASP and outcomes is independent of LA pressure, would further support PASP as a therapeutic target in HFpEF.
Several limitations of this study should be noted. Echocardiographic data at baseline and follow-up were only available in 239 patients enrolled in TOPCAT, limiting our power both to detect treatment effect on echocardiographic measures and associations between changes in echocardiographic measures and subsequent outcomes. In addition, patients with serial echocardiographic data included in this study differed significantly in demographic and clinical comorbidities from the remaining TOPCAT trial population ( Table I in the Data Supplement) , possibly limiting the generalizability of our findings. We did not account for multiple testing in our analyses, including the analysis of the relationship between change in echocardiographic measures from baseline to follow-up and subsequent outcomes, which highlights the exploratory nature of these findings. Furthermore, prominent differences in participant characteristics and response to spironolactone therapy were noted by enrollment region (United States or Russia/Georgia) in TOPCAT 11 and may confound our analysis. However, the prognostic relevance of changes in left atrial volume and PASP were also observed in analyses restricted to patients enrolled in the United States, who demonstrated hospitalization and death rates consistent with prior HFpEF outcome trials. Survivor bias is an additional potential limitation. However, among patients enrolled in the substudy, no significant differences in number of deaths before the follow-up echocardiogram were noted between the placebo and spironolactone arms in either the United States (8 versus 6, respectively, P=1.00) or Russia/Georgia (5 versus 3, respectively, P=1.00).
Conclusions
Twelve to 18 months of spironolactone therapy was not associated with improvement in LV structure or function in HFpEF. However, modest sample size and regional differences in TOPCAT limited the power of this analysis. Reduction in LA volume at follow-up was associated with a significantly lower risk of subsequent cardiovascular death, aborted cardiac arrest, or HF hospitalization. 
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